The company recognized total first quarter revenues of $16.4 million and a net loss of $30.3 million.
In a retrospective analysis, UK researchers found that long-read sequencing of HLA genes in stem cell transplantation donors and recipients led to better outcomes.
Five early customers are currently operating the Sequel II, which promises an eightfold increase in throughput, making reference genome sequencing feasible.
The US Court of Appeals upheld a previous ruling by the International Trade Commission that found Oxford Nanopore's products do not infringe on PacBio's patents.
PacBio reported that both its Q4 and full year 2018 revenues fell, but that it had launched the next version of its single-molecule sequencing platform in early access.
PacBio agreed to pay attorneys' fees to settle lawsuits brought against it by investors regarding Illumina's acquisition.
Oxford Nanopore had challenged the validity of the patent, EP3045542, which relates to DNA sample preparation for PacBio's circular consensus sequencing.
PacBio is looking to increase the yield and reduce the cost of the protocol, which enables long reads and accurate sequencing.
The company is developing a single-molecule sequencing technology intended to significantly reduce the cost and improve the accuracy of sequencing.
The firm will sell more than 14 million shares of its common stock for $4.25 per share.
Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.
University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.
The Wall Street Journal examines billing codes used by uBiome.
In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.